Looking Forward to the Future of Heparin: New Sources, Developments and Applications
This book is a printed edition of the Special Issue Looking Forward to the Future of Heparin: New Sources, Developments and Applications that was published in Molecules
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2018
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_51985 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2018 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-03842-950-0 | ||
| 020 | |a 9783038429500 | ||
| 020 | |a 9783038429494 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-03842-950-0 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a PN |2 bicssc | |
| 100 | 1 | |a Fareed, Jawed |4 auth | |
| 700 | 1 | |a Torri, Giangiacomo |4 auth | |
| 245 | 1 | 0 | |a Looking Forward to the Future of Heparin: New Sources, Developments and Applications |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2018 | ||
| 300 | |a 1 electronic resource (282 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book is a printed edition of the Special Issue Looking Forward to the Future of Heparin: New Sources, Developments and Applications that was published in Molecules | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Chemistry |2 bicssc | |
| 653 | |a alginate | ||
| 653 | |a n/a | ||
| 653 | |a edema | ||
| 653 | |a Heparin Red | ||
| 653 | |a solid lipid nanoparticles | ||
| 653 | |a Fe3O4·DA-BSA/HA | ||
| 653 | |a dermatan sulfate | ||
| 653 | |a sulfated alginate | ||
| 653 | |a porcine heparin | ||
| 653 | |a theranostics | ||
| 653 | |a low-molecular-weight heparin | ||
| 653 | |a Arixtra® | ||
| 653 | |a biomaterials | ||
| 653 | |a hepcidin | ||
| 653 | |a ovarian cancer | ||
| 653 | |a iron oxide nanoparticles | ||
| 653 | |a heparin-induced thrombocytopenia | ||
| 653 | |a bone morphogenetic protein (BMP) | ||
| 653 | |a hyaluronic acid (HA) | ||
| 653 | |a crude heparin | ||
| 653 | |a platelets | ||
| 653 | |a resistance | ||
| 653 | |a sclerostin | ||
| 653 | |a LMWH | ||
| 653 | |a gremlin | ||
| 653 | |a low molecular weight heparin (LMWH) | ||
| 653 | |a low molecular weight glycosaminoglycans | ||
| 653 | |a human plasma | ||
| 653 | |a single crystal X-ray structure | ||
| 653 | |a iron homeostasis | ||
| 653 | |a noggin | ||
| 653 | |a super paramagnetic iron oxide nanoparticles (SPION) | ||
| 653 | |a manufacturing methods | ||
| 653 | |a paclitaxel (PTX) | ||
| 653 | |a brain injury | ||
| 653 | |a bovine heparin | ||
| 653 | |a inflammation | ||
| 653 | |a qNMR | ||
| 653 | |a antithrombin | ||
| 653 | |a reference standard | ||
| 653 | |a quantitative NMR | ||
| 653 | |a enoxaparin | ||
| 653 | |a danaparoid sodium | ||
| 653 | |a NMR | ||
| 653 | |a GDNF | ||
| 653 | |a orthogonal multi-analytical methods | ||
| 653 | |a ternary complex | ||
| 653 | |a heparan sulphate | ||
| 653 | |a serglycin | ||
| 653 | |a bovine serum albumin (BSA) | ||
| 653 | |a HSQC | ||
| 653 | |a recombinant expression | ||
| 653 | |a heparin | ||
| 653 | |a heparin oligosaccharides | ||
| 653 | |a functional assay | ||
| 653 | |a BMP antagonists | ||
| 653 | |a intestinal lymphatic absorption | ||
| 653 | |a size exclusion chromatography | ||
| 653 | |a heparin coating | ||
| 653 | |a diagnosis | ||
| 653 | |a bioreactor | ||
| 653 | |a anemia | ||
| 653 | |a proteoglycan | ||
| 653 | |a heparin process | ||
| 653 | |a PCA | ||
| 653 | |a chemometric | ||
| 653 | |a fluorescent probe | ||
| 653 | |a pharmacopeia | ||
| 653 | |a affinity chromatography | ||
| 653 | |a component quantitative analysis | ||
| 653 | |a Fondaparinux sodium | ||
| 653 | |a perylene diimide dyes | ||
| 653 | |a thrombin inhibition | ||
| 653 | |a extended physicochemical characterization | ||
| 653 | |a cisplatin | ||
| 653 | |a glycosaminoglycans | ||
| 653 | |a TGF-? | ||
| 653 | |a chondroitin sulfate | ||
| 653 | |a dalteparin | ||
| 653 | |a sequence and compositional investigations | ||
| 653 | |a molecular weight | ||
| 653 | |a magnetic resonance imaging (MRI) | ||
| 653 | |a industrial | ||
| 653 | |a LC-MS | ||
| 653 | |a iduronic acid conformation | ||
| 653 | |a heparan sulfate | ||
| 653 | |a growth and differentiation factor (GDF) | ||
| 653 | |a assay | ||
| 653 | |a subarachnoid hemorrhage | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/677 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/51985 |7 0 |z DOAB: description of the publication |